ArticleJournal of the Turkish German Gynecological Association2026
Evaluation of angiopoietin-like protein 4 levels in patients with endometriosis.
Article in Journal of the Turkish German Gynecological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Endometriosis is a chronic inflammatory disorder lacking definitive laboratory diagnostic markers. Angiopoietin-like protein-4 (ANGPTL4) is a protein involved in the regulation of angiogenesis and inflammation. The aim of the present study was to evaluate serum and peritoneal fluid (PF) levels of ANGPTL4 to explore its potential role in the pathogenesis of endometriosis. Material and Methods: This prospective study included women with surgically confirmed endometriosis and age-matched healthy controls with similar demographic characteristics. Clinical and laboratory parameters, including serum ANGPTL4, anti-Müllerian hormone (AMH), and cancer antigen-125 (CA125) levels were compared between groups. In addition, PF ANGPTL4 levels were assessed in the endometriosis group. Results: Serum ANGPTL4 (512.65±46.91 vs. 177.60±11.84 ng/mL, p<0.001) and CA125 (53.52±6.05 vs. 20.10±3.18 U/mL, p<0.001) levels were significantly higher in endometriosis group. Serum ANGPTL4 positively correlated with the severity of pelvic pain and dyspareunia, serum CA125 level and PF ANGPTL4, and negatively correlated with AMH (r=0.743, p<0.001; r=0.624, p<0.001; r=0.444, p<0.001; r=0.841, p<0.001; and r=-0.380, p<0.001, respectively). Receiver operating characteristic analysis identified an optimal serum ANGPTL4 cut-off value of 188.61 ng/mL (area under the curve =0.755, sensitivity 75% and specificity 62.5%, positive predictive value 66.7%, and negative predictive value 71.4%). Conclusion: Serum ANGPTL4 levels were significantly higher in women with endometriosis and were associated with clinical and laboratory parameters. It may serve as a supportive biomarker in the clinical assessment of endometriosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.